LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB:IMUC) announced today that Helen Kim has been appointed to the Company’s Board of Directors and has been elected to be Chairperson of the Company’s Product Strategic Committee. Ms. Kim currently serves on the Board of Directors at Sunesis Pharmaceuticals and as the Chief Business Officer of NGM Biopharmaceuticals, a privately held drug discovery company.
Ms. Kim was the president and CEO of Kosan Biosciences Inc., where she restructured and repositioned the company prior to the successful sale of the company to Bristol-Myers Squibb. She also held senior positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms. Kim recently served as Chief Program Officer for the Gordon and Betty Moore Foundation. Ms. Kim has a B.S. in Chemical Engineering from Northwestern University and an M.B.A. from the University of Chicago.
“We are excited to welcome Helen Kim to our Board of Directors and as our Chairperson for our Product Strategic Committee,” said John Yu, MD, Chairman of ImmunoCellular Therapeutics. “She brings invaluable industry experience and leadership to our Board of Directors and Strategic Planning Committee.”
About ImmunoCellular Therapeutics
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com.
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or that any patents covering this vaccine will provide commercially significant protection for this product candidate. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For ImmunoCellular Therapeutics, Ltd.
Gary Nash, 212-732-4300
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical